- Home
- PSTL vs DCTH Comparison
PSTL vs DCTH Comparison
Compare PSTL & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- DCTH
- Stock Information
- Founded
- PSTL 2018
- DCTH 1988
- Country
- PSTL United States
- DCTH United States
- Employees
- PSTL N/A
- DCTH N/A
- Industry
- PSTL Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- PSTL Real Estate
- DCTH Health Care
- Exchange
- PSTL Nasdaq
- DCTH Nasdaq
- Market Cap
- PSTL 320.0M
- DCTH 352.0M
- IPO Year
- PSTL 2019
- DCTH N/A
- Fundamental
- Price
- PSTL $12.93
- DCTH $11.01
- Analyst Decision
- PSTL Strong Buy
- DCTH Strong Buy
- Analyst Count
- PSTL 1
- DCTH 4
- Target Price
- PSTL $15.50
- DCTH $21.50
- AVG Volume (30 Days)
- PSTL 141.2K
- DCTH 378.5K
- Earning Date
- PSTL 11-04-2024
- DCTH 11-08-2024
- Dividend Yield
- PSTL 7.42%
- DCTH N/A
- EPS Growth
- PSTL N/A
- DCTH N/A
- EPS
- PSTL 0.08
- DCTH N/A
- Revenue
- PSTL $72,005,000.00
- DCTH $22,644,000.00
- Revenue This Year
- PSTL N/A
- DCTH $1,605.13
- Revenue Next Year
- PSTL $12.18
- DCTH $111.67
- P/E Ratio
- PSTL $162.86
- DCTH N/A
- Revenue Growth
- PSTL 16.87
- DCTH 945.91
- 52 Week Low
- PSTL $12.79
- DCTH $3.70
- 52 Week High
- PSTL $15.15
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- PSTL 24.19
- DCTH 48.00
- Support Level
- PSTL $12.79
- DCTH $10.75
- Resistance Level
- PSTL $13.91
- DCTH $13.30
- Average True Range (ATR)
- PSTL 0.24
- DCTH 0.72
- MACD
- PSTL -0.10
- DCTH -0.13
- Stochastic Oscillator
- PSTL 9.86
- DCTH 10.19
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.